Latest news with #BRKR
Globe and Mail
7 days ago
- Business
- Globe and Mail
Bruker Announces Quarterly Dividend
Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit Forward-Looking Statements Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding expected quarterly cash dividends in 2025. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, those risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2024, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Yahoo
04-08-2025
- Business
- Yahoo
Bruker (NASDAQ:BRKR) Reports Sales Below Analyst Estimates In Q2 Earnings
Scientific instrument company Bruker (NASDAQ:BRKR). missed Wall Street's revenue expectations in Q2 CY2025, with sales flat year on year at $797.4 million. The company's full-year revenue guidance of $3.47 billion at the midpoint came in 1.5% below analysts' estimates. Its non-GAAP profit of $0.32 per share was 23.4% below analysts' consensus estimates. Is now the time to buy Bruker? Find out in our full research report. Bruker (BRKR) Q2 CY2025 Highlights: Revenue: $797.4 million vs analyst estimates of $809.2 million (flat year on year, 1.5% miss) Adjusted EPS: $0.32 vs analyst expectations of $0.42 (23.4% miss) Adjusted EBITDA: $68 million vs analyst estimates of $123.6 million (8.5% margin, 45% miss) The company dropped its revenue guidance for the full year to $3.47 billion at the midpoint from $3.52 billion, a 1.4% decrease Management lowered its full-year Adjusted EPS guidance to $2 at the midpoint, a 18% decrease Operating Margin: 1.5%, down from 6% in the same quarter last year Free Cash Flow was -$148.8 million compared to -$25.1 million in the same quarter last year Organic Revenue fell 7% year on year (7.4% in the same quarter last year) Market Capitalization: $5.76 billion Company Overview With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Thankfully, Bruker's 11.8% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Bruker's annualized revenue growth of 12.6% over the last two years aligns with its five-year trend, suggesting its demand was stable. We can better understand the company's sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Bruker's organic revenue averaged 4.8% year-on-year growth. Because this number is lower than its two-year revenue growth, we can see that some mixture of acquisitions and foreign exchange rates boosted its headline results. This quarter, Bruker missed Wall Street's estimates and reported a rather uninspiring 0.4% year-on-year revenue decline, generating $797.4 million of revenue. Looking ahead, sell-side analysts expect revenue to grow 3.2% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin Bruker has done a decent job managing its cost base over the last five years. The company has produced an average operating margin of 12.7%, higher than the broader healthcare sector. Analyzing the trend in its profitability, Bruker's operating margin decreased by 10.9 percentage points over the last five years. This performance was caused by more recent speed bumps as the company's margin fell by 12 percentage points on a two-year basis. We're disappointed in these results because it shows its expenses were rising and it couldn't pass those costs onto its customers. This quarter, Bruker generated an operating margin profit margin of 1.5%, down 4.5 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Bruker's remarkable 10.4% annual EPS growth over the last five years aligns with its revenue performance. This tells us it maintained its per-share profitability as it expanded. In Q2, Bruker reported adjusted EPS at $0.32, down from $0.52 in the same quarter last year. This print missed analysts' estimates, but we care more about long-term adjusted EPS growth than short-term movements. Over the next 12 months, Wall Street expects Bruker's full-year EPS of $2.15 to grow 23%. Key Takeaways from Bruker's Q2 Results We struggled to find many positives in these results. Its full-year EPS guidance missed and its EPS fell short of Wall Street's estimates. Overall, this was a weaker quarter. The stock traded down 3.9% to $36.48 immediately following the results. Bruker underperformed this quarter, but does that create an opportunity to invest right now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
03-07-2025
- Business
- Yahoo
Bruker Acquires Majority Stake in RECIPE, Boosts Diagnostic and Drug Monitoring Capabilities
Bruker Corporation (NASDAQ:BRKR) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 3, Bruker Corporation (NASDAQ:BRKR) acquired a majority investment in RECIPE, a manufacturer of diagnostic assays, marking a substantial step in the applied markets. The company also introduced the timsMetabo platform for advanced small molecule analysis. Bruker's therapeutic drug monitoring (TDM) and drugs of abuse (DoA) analysis capabilities are improved by the investment in RECIPE. The two companies' cooperation has resulted in the integration of Bruker's EVOQ DART-TQ system with RECIPE's ClinMass and ClinDART test kits. Although not yet US-FDA authorized, these kits are made to provide high-throughput, chromatography-free tests that can be utilized in laboratory-developed testing (LDT) methodologies. Bruker Applied Mass Spectrometry Senior Vice President Jeffrey Zonderman stressed the importance of these advancements in redefining the capabilities in applied industries, particularly for environmental analysis and TDM. Bruker Corporation (NASDAQ:BRKR), a leading American manufacturer of high-performance scientific equipment, focuses on tools for molecular and materials research, as well as industrial analysis. While we acknowledge the potential of BRKR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-06-2025
- Business
- Yahoo
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best Canadian stocks with huge upside potential. Earlier in May, AbCellera Biologics announced that the US Court of Appeals for the Federal Circuit/CAFC issued a Rule 36 Order, which affirmed the validity of its US Patent No. 10,087,408 ('the '408 Patent'). The patent specifically covers microfluidic devices and their application in culturing and selectively recovering cells. Previously, Bruker Cellular Analysis Inc., which is a subsidiary of Bruker Corporation (NASDAQ:BRKR), had challenged the claims of the '408 Patent. Bruker argued for the patent's invalidity based on allegations of anticipation and obviousness in light of prior art. However, the US Patent Trial and Appeal Board/PTAB rejected all of Bruker's arguments. The CAFC's recent decision further confirms the validity of all claims within AbCellera's '408 Patent. A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform. The 408 Patent is an integral part of ongoing multi-patent infringement litigation between AbCellera and Bruker, which is currently pending in the US District Court for the Northern District of California. AbCellera intends to continue defending its intellectual property portfolio and looks forward to proving its infringement case against Bruker in the District Court. AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines for indications with unmet medical needs in the US. Bruker Corporation (NASDAQ:BRKR) develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
11-06-2025
- Business
- Yahoo
BRKR Q1 Earnings Call: Tariffs and Funding Headwinds Offset by Product Innovation and Cost Actions
Scientific instrument company Bruker (NASDAQ:BRKR). reported Q1 CY2025 results beating Wall Street's revenue expectations , with sales up 11% year on year to $801.4 million. The company's full-year revenue guidance of $3.52 billion at the midpoint came in 0.9% above analysts' estimates. Its non-GAAP profit of $0.47 per share was 5.9% above analysts' consensus estimates. Is now the time to buy BRKR? Find out in our full research report (it's free). Revenue: $801.4 million vs analyst estimates of $768.5 million (11% year-on-year growth, 4.3% beat) Adjusted EPS: $0.47 vs analyst estimates of $0.44 (5.9% beat) The company slightly lifted its revenue guidance for the full year to $3.52 billion at the midpoint from $3.51 billion Management lowered its full-year Adjusted EPS guidance to $2.44 at the midpoint, a 9.5% decrease Operating Margin: 4%, down from 9% in the same quarter last year Organic Revenue rose 2.9% year on year (1.6% in the same quarter last year) Market Capitalization: $6.16 billion Bruker's first quarter results reflected both the company's diversified customer base and the impact of recent acquisitions. CEO Frank Laukien highlighted that biopharma demand strengthened, and the Bruker Scientific Instruments segment achieved 5.1% organic growth, despite declining U.S. and China academic/government orders. Laukien noted that 'our teams executed very well under significant uncertainties in key markets,' and credited new product launches in spatial biology and molecular diagnostics for supporting growth. The company's BioSpin and CALID groups benefited from robust research and diagnostics activity, but the BEST segment saw a decline due to weaker MRI superconductor demand and tough comparisons from last year. Management remained cautious about the sustainability of academic/government funding, emphasizing that delayed China stimulus and new tariffs weighed on segment performance. Looking ahead, Bruker's updated guidance reflects both ongoing challenges and mitigation strategies. CEO Frank Laukien explained that U.S. policy changes and tariffs are expected to create a $100 million gross revenue headwind this year, mostly from academic/government market pressures. At the same time, Laukien outlined actions to offset these impacts, including pricing adjustments, supply chain reengineering, and cost management. CFO Gerald Herman added that mitigation efforts should cover more than half of the operating profit headwind in 2025, with full offset expected by 2026. Management remains focused on product innovation and international growth, while acknowledging that further clarity on U.S. federal research policy and global tariffs will be critical for medium-term outlooks. Management attributed first quarter growth to biopharma demand, recent acquisitions, and new product launches, but acknowledged that academic/government funding reductions and tariffs are creating significant headwinds for certain segments. Biopharma momentum: Bruker saw continued improvement in biopharma demand, with CEO Frank Laukien stating that "biopharma has been increasing from a weak base last year" and is now supported by a broader set of tools, including spatial biology and automation platforms. This trend helped offset challenges in the academic/government sector. Academic/government weakness: The company experienced a notable decline in U.S. academic and government (ACA/GOV) orders, with Laukien estimating a 20-25% revenue drop for this market in 2025. Management reported delays but not cancellations so far, and expressed uncertainty about when NIH and NSF funding would stabilize. Impact of tariffs and policy: Bruker quantified a $100 million gross revenue headwind from U.S. federal funding changes, lower China stimulus, and new import tariffs—especially a 125% Chinese tariff on some U.S. exports. CFO Gerald Herman explained that about $90 million of operating profit is at risk before mitigation actions. Recent acquisitions and product launches: The company launched new products in spatial biology, NMR (nuclear magnetic resonance), and molecular diagnostics, while integrating acquisitions like Chemspeed and ELITech. Laukien described these as "meaningful post-genomic innovations" that support growth outside of volatile funding sources. Cost and supply chain actions: To address margin pressures, Bruker is implementing targeted price increases, cost reductions, and supply network changes. Laukien said these efforts should offset more than half of the 2025 headwinds, with the remainder addressed by 2026 through further operational changes. Bruker's outlook for 2025 is shaped by anticipated weakness in academic and government markets, tariff impacts, and the pace of mitigation measures, with product innovation and international expansion as key offsetting factors. Mitigation of margin headwinds: Management expects pricing actions, cost controls, and supply chain reengineering to offset over half of the 2025 operating profit headwind, with benefits accelerating in the second half of the year and fully realized in 2026. Gerald Herman noted that supply chain adjustments and workforce flexibility, especially in Europe, will help manage fixed costs. Product innovation and diversification: Bruker is relying on new launches in spatial biology, molecular diagnostics, and automation to drive demand in biopharma and industrial markets. Laukien emphasized that recent acquisitions and expanded product offerings are helping to reduce reliance on academic/government funding and diversify revenue streams. Academic/government funding and tariffs remain risks: Management cautioned that further declines in U.S. and China academic/government funding, as well as uncertainty around future tariff policies, could continue to pressure results. The company has not assumed any major improvement in China stimulus or U.S. federal research budgets for the remainder of 2025. In the coming quarters, the StockStory team will focus on (1) evidence that cost and supply chain mitigation actions are offsetting margin and revenue headwinds as planned, (2) stabilization or recovery in U.S. and China academic/government funding trends, and (3) continued growth in biopharma and diagnostics segments supported by new product launches. Progress on integrating recent acquisitions and clarity on global tariff policies will also be key indicators. Bruker currently trades at a forward P/E ratio of 14.7×. Should you double down or take your chips? Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
